EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
Source: SeekingAlpha
2025-06-12 11:03:51 ET
Investment Overview
Back in January this year, I covered EyePoint Pharmaceuticals, Inc. ( EYPT ) in a note for Seeking Alpha , calling its stock a "risky buy" ahead of a key readout for its lead and only clinical stage drug candidate Duravyu - vorolanib intravitreal insert - in patients suffering from diabetic macular edema - a serious eye condition that can result in vision loss....
Read the full article on Seeking Alpha
For further details see:
EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
Unity Biotechnology Inc.
NASDAQ: UBX
UBX Trading
-41.13% G/L:
$0.2001 Last:
3,847,602 Volume:
$0.2824 Open:
UBX Latest News
UBX Stock Data
$965,603
15,835,198
1.75%
7
551621%
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
